Nucleoside phosphoramidate prodrugs
View Patent ↗Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
1. A compound represented by the following formula:
wherein
(a) R 1 is phenyl;
(b) R 2 is hydrogen;
(c) R 3a and R 3b independently H or CH 3 ;
(d) R 4 is i Pr, n Pr, n Bu, 2-butyl, t Bu, or benzyl;
(e) R 5 is H;
(f) R 6 is CH 3 ;
(g) X is Cl;
(h) Y is OH; and
(i) R 7 and R 8 are H.
2. The compound of claim 1 , having the following structure:
3. The compound of claim 1 , having the following structure:
4. The compound of claim 1 , having the following structure:
5. The compound of claim 1 , having the following structure:
6. A pharmaceutical formulation comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
7. A method of treating HCV comprising administering a therapeutically effective amount of a compound of claim 4 to a human subject in need thereof.
8. The method of claim 7 further comprising administering to the human subject a therapeutically effective amount of another antiviral agent.
9. The methods of claim 8 , wherein the another antiviral agent is an NS5A inhibitor.
10. The methods of claim 8 , wherein the another antiviral agent is an NS3 inhibitor.
11. The method of claim 10 , further comprising administering to the human subject a therapeutically effective amount of an NS5A inhibitor.